Lymphotoxin β receptor-dependent control of lipid homeostasis

James C. Lo, Yugang Wang, Alexei V. Tumanov, Michelle Bamji, Zemin Yao, Catherine A. Reardon, Godfrey S. Getz, Yang Xin Fu

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Hyperlipidemia, one of the most important risk factors for coronary heart disease, is often associated with inflammation. We identified lymphotoxin (LT) and LIGHT, tumor necrosis factor cytokine family members that are primarily expressed on lymphocytes, as critical regulators of key enzymes that control lipid metabolism. Dysregulation of LIGHT expression on T cells resulted in hypertriglyceridemia and hypercholesterolemia. In low-density lipoprotein receptor-deficient mice, which lack the ability to control lipid levels in the blood, inhibition of LT and LIGHT signaling with a soluble lymphotoxin β receptor decoy protein attenuated the dyslipidemia. These results suggest that the immune system directly influences lipid metabolism and that LT modulating agents may represent a novel therapeutic route for the treatment of dyslipidemia.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalScience
Volume316
Issue number5822
DOIs
StatePublished - Apr 13 2007

Fingerprint

Lymphotoxin-alpha
Homeostasis
Lipids
Dyslipidemias
Lipid Metabolism
Light
Aptitude
LDL Receptors
Hypertriglyceridemia
Hypercholesterolemia
Hyperlipidemias
Coronary Disease
Immune System
Tumor Necrosis Factor-alpha
Lymphocytes
Cytokines
Inflammation
T-Lymphocytes
Enzymes
Proteins

ASJC Scopus subject areas

  • General

Cite this

Lo, J. C., Wang, Y., Tumanov, A. V., Bamji, M., Yao, Z., Reardon, C. A., ... Fu, Y. X. (2007). Lymphotoxin β receptor-dependent control of lipid homeostasis. Science, 316(5822), 285-288. https://doi.org/10.1126/science.1137221

Lymphotoxin β receptor-dependent control of lipid homeostasis. / Lo, James C.; Wang, Yugang; Tumanov, Alexei V.; Bamji, Michelle; Yao, Zemin; Reardon, Catherine A.; Getz, Godfrey S.; Fu, Yang Xin.

In: Science, Vol. 316, No. 5822, 13.04.2007, p. 285-288.

Research output: Contribution to journalArticle

Lo, JC, Wang, Y, Tumanov, AV, Bamji, M, Yao, Z, Reardon, CA, Getz, GS & Fu, YX 2007, 'Lymphotoxin β receptor-dependent control of lipid homeostasis', Science, vol. 316, no. 5822, pp. 285-288. https://doi.org/10.1126/science.1137221
Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA et al. Lymphotoxin β receptor-dependent control of lipid homeostasis. Science. 2007 Apr 13;316(5822):285-288. https://doi.org/10.1126/science.1137221
Lo, James C. ; Wang, Yugang ; Tumanov, Alexei V. ; Bamji, Michelle ; Yao, Zemin ; Reardon, Catherine A. ; Getz, Godfrey S. ; Fu, Yang Xin. / Lymphotoxin β receptor-dependent control of lipid homeostasis. In: Science. 2007 ; Vol. 316, No. 5822. pp. 285-288.
@article{947e68ed601749d0916c415630778b33,
title = "Lymphotoxin β receptor-dependent control of lipid homeostasis",
abstract = "Hyperlipidemia, one of the most important risk factors for coronary heart disease, is often associated with inflammation. We identified lymphotoxin (LT) and LIGHT, tumor necrosis factor cytokine family members that are primarily expressed on lymphocytes, as critical regulators of key enzymes that control lipid metabolism. Dysregulation of LIGHT expression on T cells resulted in hypertriglyceridemia and hypercholesterolemia. In low-density lipoprotein receptor-deficient mice, which lack the ability to control lipid levels in the blood, inhibition of LT and LIGHT signaling with a soluble lymphotoxin β receptor decoy protein attenuated the dyslipidemia. These results suggest that the immune system directly influences lipid metabolism and that LT modulating agents may represent a novel therapeutic route for the treatment of dyslipidemia.",
author = "Lo, {James C.} and Yugang Wang and Tumanov, {Alexei V.} and Michelle Bamji and Zemin Yao and Reardon, {Catherine A.} and Getz, {Godfrey S.} and Fu, {Yang Xin}",
year = "2007",
month = "4",
day = "13",
doi = "10.1126/science.1137221",
language = "English (US)",
volume = "316",
pages = "285--288",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5822",

}

TY - JOUR

T1 - Lymphotoxin β receptor-dependent control of lipid homeostasis

AU - Lo, James C.

AU - Wang, Yugang

AU - Tumanov, Alexei V.

AU - Bamji, Michelle

AU - Yao, Zemin

AU - Reardon, Catherine A.

AU - Getz, Godfrey S.

AU - Fu, Yang Xin

PY - 2007/4/13

Y1 - 2007/4/13

N2 - Hyperlipidemia, one of the most important risk factors for coronary heart disease, is often associated with inflammation. We identified lymphotoxin (LT) and LIGHT, tumor necrosis factor cytokine family members that are primarily expressed on lymphocytes, as critical regulators of key enzymes that control lipid metabolism. Dysregulation of LIGHT expression on T cells resulted in hypertriglyceridemia and hypercholesterolemia. In low-density lipoprotein receptor-deficient mice, which lack the ability to control lipid levels in the blood, inhibition of LT and LIGHT signaling with a soluble lymphotoxin β receptor decoy protein attenuated the dyslipidemia. These results suggest that the immune system directly influences lipid metabolism and that LT modulating agents may represent a novel therapeutic route for the treatment of dyslipidemia.

AB - Hyperlipidemia, one of the most important risk factors for coronary heart disease, is often associated with inflammation. We identified lymphotoxin (LT) and LIGHT, tumor necrosis factor cytokine family members that are primarily expressed on lymphocytes, as critical regulators of key enzymes that control lipid metabolism. Dysregulation of LIGHT expression on T cells resulted in hypertriglyceridemia and hypercholesterolemia. In low-density lipoprotein receptor-deficient mice, which lack the ability to control lipid levels in the blood, inhibition of LT and LIGHT signaling with a soluble lymphotoxin β receptor decoy protein attenuated the dyslipidemia. These results suggest that the immune system directly influences lipid metabolism and that LT modulating agents may represent a novel therapeutic route for the treatment of dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=34247371874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247371874&partnerID=8YFLogxK

U2 - 10.1126/science.1137221

DO - 10.1126/science.1137221

M3 - Article

C2 - 17431181

AN - SCOPUS:34247371874

VL - 316

SP - 285

EP - 288

JO - Science

JF - Science

SN - 0036-8075

IS - 5822

ER -